As Vice President, Chief Medical Officer for the TB Alliance, Dr. Maria Beumont will develop and lead the clinical strategy and provide oversight of clinical trial planning and execution of promising anti-tuberculosis drugs and regimens.

Dr. Beumont joined the TB Alliance in January 2022 with more than 20 years of experience in pharmaceutical development from early to late stage. She was previously Senior Medical Director at Janssen where she was deeply involved in the development and approval of compounds for the treatment of hepatitis C, and most recently held the role of Hepatitis Franchise Medical lead.  Before joining Janssen Pharmaceuticals in 2006, she was Medical Director at Chiron corporation working primarily on the application of IL-2 in the treatment of HIV, and prior to that she served as the Director of HIV Services for the City of Philadelphia at the Philadelphia Department of Public Health.

Maria received her MD degree from the University of Buenos Aires, Argentina, the moved to the United States where she completed a residency in Internal Medicine at Abington Memorial Hospital followed by a Fellowship in Infectious Diseases at the University of Pennsylvania.